Analysts Expect Nektar Therapeutics (NKTR) Will Post Earnings of -$0.35 Per Share

Equities analysts predict that Nektar Therapeutics (NASDAQ:NKTR) will report ($0.35) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Nektar Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.30) and the lowest estimate coming in at ($0.40). Nektar Therapeutics posted earnings of ($0.28) per share during the same quarter last year, which would indicate a negative year over year growth rate of 25%. The business is scheduled to announce its next earnings report on Wednesday, March 7th.

According to Zacks, analysts expect that Nektar Therapeutics will report full-year earnings of ($0.75) per share for the current financial year, with EPS estimates ranging from ($0.81) to ($0.71). For the next year, analysts expect that the firm will report earnings of ($1.21) per share, with EPS estimates ranging from ($1.58) to ($0.57). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that follow Nektar Therapeutics.

Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported $0.37 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.21 by $0.16. Nektar Therapeutics had a negative return on equity of 190.68% and a negative net margin of 42.08%. The firm had revenue of $152.90 million during the quarter, compared to analyst estimates of $126.50 million. During the same period last year, the company earned ($0.32) EPS. Nektar Therapeutics’s quarterly revenue was up 321.2% compared to the same quarter last year.

A number of equities research analysts recently issued reports on the company. Canaccord Genuity Group raised their price target on Nektar Therapeutics from $35.00 to $50.00 and gave the stock a “buy” rating in a research note on Wednesday, November 15th. Cowen assumed coverage on Nektar Therapeutics in a research note on Tuesday, November 7th. They set an “outperform” rating for the company. Canaccord Genuity assumed coverage on Nektar Therapeutics in a research note on Thursday, November 9th. They set a “buy” rating and a $35.00 price target for the company. Roth Capital set a $45.00 price target on Nektar Therapeutics and gave the stock a “buy” rating in a research note on Monday, November 13th. Finally, Zacks Investment Research downgraded Nektar Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and twelve have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $38.08.

In other Nektar Therapeutics news, SVP Stephen K. Doberstein sold 396,323 shares of the firm’s stock in a transaction on Wednesday, November 8th. The stock was sold at an average price of $29.00, for a total transaction of $11,493,367.00. Following the transaction, the senior vice president now directly owns 52,016 shares in the company, valued at approximately $1,508,464. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Howard W. Robin sold 83,334 shares of the firm’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $23.57, for a total value of $1,964,182.38. Following the transaction, the chief executive officer now owns 235,838 shares in the company, valued at $5,558,701.66. The disclosure for this sale can be found here. Insiders have sold a total of 614,017 shares of company stock worth $20,587,527 over the last 90 days. 5.44% of the stock is currently owned by company insiders.

Several large investors have recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Nektar Therapeutics by 14.1% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,603 shares of the biopharmaceutical company’s stock valued at $110,000 after acquiring an additional 692 shares during the period. Ameritas Investment Partners Inc. increased its holdings in shares of Nektar Therapeutics by 7.7% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 13,011 shares of the biopharmaceutical company’s stock valued at $254,000 after acquiring an additional 929 shares during the period. Amalgamated Bank increased its holdings in shares of Nektar Therapeutics by 8.7% in the 2nd quarter. Amalgamated Bank now owns 20,563 shares of the biopharmaceutical company’s stock valued at $402,000 after acquiring an additional 1,644 shares during the period. Shelton Capital Management increased its holdings in shares of Nektar Therapeutics by 12.5% in the 2nd quarter. Shelton Capital Management now owns 15,283 shares of the biopharmaceutical company’s stock valued at $299,000 after acquiring an additional 1,696 shares during the period. Finally, Strs Ohio increased its holdings in shares of Nektar Therapeutics by 16.3% in the 3rd quarter. Strs Ohio now owns 16,400 shares of the biopharmaceutical company’s stock valued at $393,000 after acquiring an additional 2,300 shares during the period. Institutional investors and hedge funds own 96.01% of the company’s stock.

Shares of Nektar Therapeutics (NASDAQ:NKTR) traded up $0.87 during mid-day trading on Friday, hitting $68.90. The company had a trading volume of 6,304,500 shares, compared to its average volume of 2,190,000. Nektar Therapeutics has a 52-week low of $11.41 and a 52-week high of $73.95. The company has a debt-to-equity ratio of 2.91, a current ratio of 4.14 and a quick ratio of 3.99. The company has a market cap of $10,850.00, a price-to-earnings ratio of -97.04 and a beta of 1.81.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by Markets Daily and is owned by of Markets Daily. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://www.themarketsdaily.com/2018/01/11/analysts-expect-nektar-therapeutics-nktr-will-post-earnings-of-0-35-per-share.html.

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Get a free copy of the Zacks research report on Nektar Therapeutics (NKTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply